- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Stereotactic Body Radiation Therapy (SBRT), cisplatin or carboplatin-based
- Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Nonsquamous Nonsmall Cell Neoplasm of Lung, Nonsmall Cell Lung Cancer Stage III
- Interventions
- Pemetrexed, Carboplatin, Radiation Therapy, Cisplatin, Lobectomy
- Drug · Radiation · Procedure
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Durvalumab, Danvatirsen, Oleclumab, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- Pleural Neoplasms
- Interventions
- pemetrexed, cisplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 7
- States / cities
- San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 4 more
- Conditions
- Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Metastatic Urothelial Carcinoma, MTAP Negative
- Interventions
- Avelumab, Pemetrexed
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non Small Cell Lung Carcinoma
- Interventions
- pemetrexed, gemcitabine, cisplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,713 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 18
- States / cities
- Sacramento, California • Torrance, California • Jacksonville, Florida + 15 more
- Conditions
- Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
- Interventions
- Nivolumab, (8gy x 3), Platinum Doublet
- Drug · Radiation
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Mesothelioma, Bladder Cancer, Ovarian Cancer, Peritoneal Cancer, Thymoma, Thymus Cancer, Uterine Cervical Cancer
- Interventions
- Bosutinib, Pemetrexed
- Drug
- Lead sponsor
- Nagla Abdel Karim
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Medical Oncology
- Interventions
- BAY 94-9343, Pemetrexed, Cisplatin
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Bethesda, Maryland • Detroit, Michigan + 1 more
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Non-Small Cell Carcinoma of Lung, TNM Stage 4
- Interventions
- Granulocyte-Macrophage Colony-Stimulating Factor, Pembrolizumab, pemetrexed, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
- Interventions
- Pemetrexed, BIBW 2992, Cisplatin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 7
- States / cities
- Fayetteville, Arkansas • Montebello, California • Miami, Florida + 4 more
- Conditions
- Non-small Cell Lung Cancer, Starting Pemetrexed Based Therapy, Unresectable Cancer
- Interventions
- Baseline 18F-thymidine (FLT) PET/CT, Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT "flare", Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Malignant Peritoneal Mesothelioma, Peritoneal Mesothelioma, Mesothelioma, Mesothelioma, Malignant, Malignant Mesothelioma
- Interventions
- Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 13
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • St Louis, Missouri + 10 more
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 29
- States / cities
- San Diego, California • Plainville, Connecticut • Weston, Florida + 19 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, pemetrexed disodium, radiation
- Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 148
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 97 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Viagenpumatucel-L, Metronomic Cyclophosphamide, Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
- Drug
- Lead sponsor
- Heat Biologics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 16
- States / cities
- Rogers, Arkansas • La Jolla, California • Los Angeles, California + 13 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Pembrolizumab, Pemetrexed, Oxaliplatin, Dexamethasone, Folic Acid, Vitamin B-12
- Drug · Dietary Supplement
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 15
- States / cities
- Gainesville, Florida • Decatur, Illinois • Effingham, Illinois + 8 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Tetrathiomolybdate
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Neoplasms
- Interventions
- Sunitinib, Pemetrexed, Cisplatin, Carboplatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Nonsquamous Non-small Cell Lung Cancer
- Interventions
- Vudalimab + Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
- Combination Product
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Glendale, Arizona • Norwich, Connecticut • Fredericksburg, Virginia
- Conditions
- Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Pembrolizumab, Pemetrexed, Carboplatin, Comprehensive Geriatric Assessment, Questionnaire Administration, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 505
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 318 more
- Conditions
- NSCLC
- Interventions
- Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- EQRx International, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Springdale, Arkansas • Hollywood, Florida • Pembroke Pines, Florida + 5 more
- Conditions
- Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer, Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer
- Interventions
- Cisplatin, Pemetrexed, Gemcitabine
- Drug
- Lead sponsor
- Western Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung
- Interventions
- NEO-PV-01, Pembrolizumab, Adjuvant, Carboplatin, Pemetrexed
- Biological · Other · Drug
- Lead sponsor
- BioNTech US Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Boston, Massachusetts • St Louis, Missouri + 1 more